Business & Finance

Lilly shares on track for worst day since 2021 after downbeat Zepbound sales forecast

14 January 2025, 2:12 pm 1 minute

Reuters was two-and-a-half minutes ahead of rivals on Eli Lilly’s unscheduled trading update, which showed fourth-quarter sales of its weight-loss drug Zepbound would miss Wall Street estimates. The drugmaker’s shares slumped 8% on the news.

Article Tags

Topics of Interest: Business & Finance

Type: Reuters Best

Sectors: Business & Finance

Regions: Americas

Win Types: Speed

Story Types: Exclusive / Scoop

Media Types: Text

Customer Impact: Important Regional Story

Share this article

Work Email Address *

Country *

I'd like to receive communications about Reuters resources, events, products, or services.

(Please note you can manage and update your preferences at any time.) By submitting your details, you are agreeing to receive communications about Reuters resources, events, products, or services. By submitting your details, you are also acknowledging that you have read and understood our: Privacy Statement.

By submitting your details, you are agreeing to receive communications about Reuters resources, events, products, or services. By submitting your details, you are also acknowledging that you have read and understood our: Privacy Statement. * required field

Work Email Address *

Country *

More of Reuters Best

How bond vigilantes could check Trump’s power

Lilly shares on track for worst day since 2021 after downbeat Zepbound sales forecast

More of Reuters Best

How bond vigilantes could check Trump’s power

Meta warns India antitrust ruling could force roll back of features, hurt business

Lilly shares on track for worst day since 2021 after downbeat Zepbound sales forecast

Barrick to suspend operations in Mali after gold seized